NCT Number: NCT00413738
Prevention of Catheter-Related Bloodstream Infection in Patients With Hemato-Oncological Disease
The aim of this prospective randomised controlled trial is to compare the incidence of catheter-related bloodstream infection in 2 groups of patients with hemato-oncological disease:
Group A: heparin-coated central venous catheters (Control Group) Group B: antiseptic-coated (chlorhexidine-silver sulfadiazine) central venous catheters
Looking for future studies?
Notify MeKey information
Conditions
Age range
4 year–65 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
About this study
Central venous lines (CVLs) are commonly used in patients with hemato-oncological disease for indications such as monitoring of hemodynamics and administration of blood products, chemotherapy, parenteral nutrition, and infusion fluids. Complications of catheterization include mechanical (arterial puncture, pneumothorax), thrombotic and infectious complications.Data from the National Nosocomial Infections Surveillance system (US) between January 1992 and February 1998 showed that catheter-related bloodstream infection (CRBI) is the third most frequent nosocomial infection and accounts for 14% of all nosocomial infections. CRBIs prolong hospital stays from 7 to 21 days and account for an estimated increase in hospital costs of $ 3000-40 000 per patient.In addition, an estimated 10-20% attributable mortality owing to nosocomial CRBI has been reported.
Besides the aseptic measures both for the insertion of the catheter and its maintenance, many different approaches have been attempted to decrease central venous catheter infections: heparin-coated catheters, as well as antimicrobial and antiseptic impregnated CVLs.
Heparin-coated catheters:
Studies have shown that catheter-related infection may be due to fibrin deposition associated with catheters. Interventions designed to decrease fibrin deposition and thrombus formation have the potential to reduce catheter-related infections.
Antiseptic-coated catheters:
Catheter colonization is an essential prerequisite in the pathogenesis of CRBI. Colonization results from contamination of the catheters during insertion and subsequent care. There are data to suggest that contamination often occurs at the time of insertion. Therefore, attempts to prevent colonization focus on the elimination of initial contamination through aseptic technique and on the retardation of subsequent migration of organisms into the bloodstream.
Recently, catheters impregnated with chlorhexidine and silver sulfadiazine have been developed to reduce the risk of catheter-related sepsis. Initial studies on humans showed that such impregnation could effectively reduce colonization in short-term catheterisation, but they have been less conclusive in showing the benefit of such impregnation in reducing catheter-related bloodstream infections.The efficacy of these antiseptic catheters varies in different subgroup populations.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patients are eligible for the study if they are between 4 and 65 years of age and have a short-term non-tunneled percutaneous CVL.
Exclusion criteria
- The presence of a CVL at admission
- An anticipated duration of catheterization of less than 5 days or more than 35 days
- A contraindication to the use of subclavian catheterization due to major blood coagulation disorders (ie, platelet count < 50 x 10^9/L)
- Disseminated intravascular coagulation
- Prior allergic reactions to heparin or to CSS
- An aberrant course of the CVL (jugular vein)
- An absence of catheter-tip culture at the time of catheter removal.
Treatment and study plan
Primary outcomes
-
The primary outcome of this prospective randomised controlled trial is to compare the incidence of catheter-related bloodstream infection in 2 groups of patients with hemato-oncological disease:
-
Group A: heparin-coated central venous catheters (Control Group)
-
Group B: antiseptic-coated (chlorhexidine-silver sulfadiazine) central venous catheters
Secondary outcomes
-
Analysis of variables that may be significant for the development of CRBI (age, gender, underlying disease...)
Sponsors and collaborators
Lead sponsor
Centre National de Greffe de Moelle Osseuse
Other Gov
Registry information
Official study title
Prevention of Catheter-Related Bloodstream Infection in Patients With Hemato-Oncological Disease.A Randomized Controlled Trial:Heparin-Coated Central Venous Catheters Versus Antiseptic-Coated Central Venous Catheters
Important dates
- Study start
- 2006
- Study completion
- 2009
- First posted
- Dec 20, 2006
- Registry last updated
- Jan 27, 2009
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Cross-sectional Characterization of Idiopathic Bronchiectasis
NCT01264055
Bronchial Diseases, Bronchiectasis
Stanford, California, United States
View Trial DetailsTattooing and Piercing Among Medical Students
NCT07673484
Allergic Contact Dermatitis, Cicatrix
Küçükçekmece, Istanbul, Turkey (Türkiye)
View Trial DetailsNew Techniques for Using a Saline Wash as a Diagnostic Tool for Pneumocystis Pneumonia
NCT00342589
Bacterial Infections and Mycoses, Infection
Bethesda, Maryland, United States
View Trial DetailsMetagenomic Next-Generation Sequencing for the Diagnosis of Fracture-related Infection
NCT07256405
Bone, Fracture
Marseille, Bouches-du-Rhône, France
View Trial Details